Shots:

• The initiation of a rolling submission to Health Canada for molnupiravir (bid- for 5 days) to treat COVID-19 is based on the P-II interim results from the P-II/III MOVe-OUT clinical trials. The therapy is being developed in collaboration with Ridgeback
• The submission was accepted under the Minister of Health’s interim order and enables the review of early safety- quality and efficacy data while later-stage clinical trials are ongoing
• The therapy is being currently evaluated in P-III MOVe-OUT clinical trials trial in 1550 non-hospitalized adults in a ratio (1:1) with SARS-CoV-2 with at least one risk factor associated with poor disease outcomes

Ref: Newswire.ca | Image: Merck